Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).
C. Zhou
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
Y. L. Wu
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
G. Chen
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
J. F. Feng
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
X. Liu
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
C. Wang
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
S. Zhang
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
J. Wang
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
S. Zhou
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
S. Ren
No relevant relationships to disclose
S. Lu
Research Funding - Chinese Thoracic Oncology Group; Roche; Shanghai Pulmonary Hospital; Tongji University
L. Zhang
No relevant relationships to disclose